An industry-supported symposium at ICNMD 2024

Spotlight on nmDMD: exploring a targeted treatment option

This symposium is organised and sponsored by PTC Therapeutics International Limited and is intended for healthcare professionals only.

Sunday 27 October 2024 | 1:00–2:00 pm AWST

Information on PTC products will be discussed during this symposium that are not approved by the TGA for use in Australia.

Your information

*Required field

Terms of use
The personal data collected by this site is intended for PTC Therapeutics International Limited and Oxford PharmaGenesis for meeting registration and delivering conference related content. Organisers may transfer data you provided for processing to countries outside your country of residence. Organisers implement appropriate measures to ensure that any cross-border transfer of personal data remains protected and secure. By submitting your registration data, you consent to the information being shared with those employees and third parties with a business need for access to your information. We take reasonable steps to protect against the loss, misuse or unauthorised alteration of personally identifiable information collected through this registration site.

You might be able to access live links to other Internet sources from our website and electronic materials provided; we do not endorse, approve, certify, or control these external links and do not guarantee the accuracy, completeness, efficacy, timeliness or correct sequencing of information located at such sites. We make no representations or warranties with respect to any linked sites. Additionally, you should be aware that your use of any linked sites is subject to the terms and conditions applicable to that website.
Thank you for registering your interest!

You will receive an email with your registration details.
Oops! Something went wrong while submitting the form.

Address

River View Room 4,
Perth Convention and Exhibition Centre,
Perth, WA, Australia

All individuals must be registered to attend ICNMD 2024 to participate in this industry-supported symposium.

ICNMD 2024

Information on PTC products will be discussed during this symposium that are not approved by the TGA for use in Australia.

Lunch will be provided.

Take a look at the symposium agenda

Find out more about our expert faculty and the objectives of this symposium.

Click here to download

This symposium is organised and sponsored by PTC Therapeutics International Limited and is intended for healthcare professionals only. This presentation was approved by the Scientific Program Committee as an independent activity held in conjunction with the 18th International Congress on Neuromuscular Diseases. This presentation is not sponsored or endorsed by ICNMD 2024.

https://www.ptcbio.com/privacy-statement/
https://www.ptcbio.ie/privacy-statement
https://www.ptcbio.com/terms-of-use/
Oxford PharmaGenesis privacy statement

nmDMD, nonsense mutation Duchenne muscular dystrophy; TGA, Therapeutic Goods Administration.

© 2024 PTC Therapeutics International Limited. All rights reserved. Trademarks, registered or otherwise, are the property of their respective owners. PTC Therapeutics International Limited, Unit 1, 52–55 Sir John Rogerson’s Quay, Dublin 2, D02 NA07, Ireland.
MED-ALL-ATLN-2400015 | Date of preparation: September 2024